Claims for Patent: 5,401,635

Summary for Patent: 5,401,635

Title:	Nucleic acids encoding human prohibitin mutants and detection thereof
Abstract:	A human prohibitin gene, a protein coded for by said gene, a gene analysis reagent to be used with them, and a quantitative determination of prohibitin in a biological sample by an immunological technique with the use of an antihuman prohibitin antibody and a method for analyzing a prohibitin gene of a human tissue for the occurrence of mutation by the PCR method with the use of oligonucleotides having partial base sequences of said gene as primers.
Inventor(s):	Nakamura; Yusuke (Tokyo, JP), Sato; Takaaki (Tokyo, JP)
Assignee:	Cancer Institute (Tokyo, JP) Eisai Co., Ltd. (Tokyo, JP)
Application Number:	08/114,461
Patent Claims:	1. An isolated intron DNA fragment from a human prohibitin gene consisting of nucleotides 134 to 152 or 491 to 510 of SEQ ID NO: 2. 2. A method for human prohibitin gene analysis, comprising the steps of obtaining a human sample containing DNA; amplifying a prohibitin gene fragment of the DNA comprising exon 4 in a polymerase chanin reaction comprising said DNA, deoxynucleotide triphospates, polymerase, and a primer pair, wherein said primer pair consists of one primer targeted to each of the first two intron segments of SEQ ID NO: 2, said intron segments flanking said exon 4; and analyzing the amplified prohibitin gene fragment for the occurrence of mutation by nucleotide sequence determination, RNase protection assays, or single-strand conformation polymorphism assays. 3. The method for human prohibitin gene analysis as claimed in claim 2, wherein said primer is one of an oligonucleotide having a base sequence of the 134- to 152-positions in the base sequence SEQ ID NO: 2 and an oligonucleotide having the antisense code of the 491- to 510-positions in the base sequence SEQ ID NO:2. 4. A reagent for human prohibitin gene analysis for the occurrence of mutation, wherein said reagent is a primer selected from the group consisting of an oligonucleotide having the base sequence of the 134- to 152-positions in the base sequence SEQ ID NO: 2 and an oligonucleotide having an antisense code of the 491- to 510-positions in the base sequence SEQ ID NO: 2. 5. A cDNA having the sequence of SEQ ID NO: 1 except that codon GTC, the codon for valine, at the 88-amino acid position is GCC, the codon for alanine. 6. A cDNA having the sequence of SEQ ID NO: 1 except that codon CGC, the codon for arginine, at the 105-amino acid position is CAC, the codon for histidine. 7. A DNA having the sequence of SEQ ID NO: 1 except that a dinucleotide CA in CACAC at the 320- to 324-base positions is lacking. 8. A DNA having the sequence of SEQ ID NO: 2 except that the base C at the 409-base position is T. 9. A host cell transformed by a plasmid which can be expressed in the host cell and which plasmid has inserted therein the cDNA as claimed in claim 5. 10. A host cell transformed by a plasmid which can be expressed in the host cell and which plasmid has inserted therein the cDNA as claimed in claim 6.

Details for Patent 5,401,635

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2012-03-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2012-03-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2012-03-28